Abstract Changes over 50 years of research on antipsychotics in schizophrenia have
occurred. A scientometric synthesis of such changes over time and a measure of …

Background The degree of efficacy, safety, quality, and certainty of meta-analytic evidence of
biological non-pharmacological treatments in mental disorders is unclear. Methods We …

The British Association for Psychopharmacology developed an evidence-based consensus
guideline on the management of catatonia. A group of international experts from a wide …

Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

Objectives: This guideline provides recommendations for the clinical management of
schizophrenia and related disorders for health professionals working in Australia and New …

Clinical practice guidelines (CPGs) translate evidence into recommendations to improve
patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a …

Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

Schizophrenia is a debilitating illness with a lifetime prevalence estimate of 0.6% and
consists of symptoms from the positive, negative, and cognitive domains. Social support …

Objective: To familiarize the reader with the role of electroconvulsive therapy (ECT) in
current psychiatric medicine. Method: We review clinical indications for ECT, patient …

Background The question of which antipsychotic drug should be preferred for the treatment
of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide …